Summary
Autologous hemotherapy does not have any relevance in the current reimbursement system but can be reflected by coding in the OPS catalogue 2006 within the G-DRG (German Refined Diagnosis Related Group) system. Code quality of these procedures can certainly be improved in order to ameliorate the basis of calculation within the DRGs. Autologous procedures play an important role within the perioperative DRG process with respect to quality improvement and cost reduction. Calculation algorithms which are generally valid should be established to precisely evaluate previous findings. Schleppers costs as regards the calculation. Interestingly, only 133 out of the total of 214 participating hospitals were also included in the calculation for the catalogue in the year 2005. Thus, 81 hospitals contributed to create 'newly mixed data'. 9 of the clinics included in the calculation were university clinics. Around 3.5 million data were supplied which increases the total of delivered data concerning reimbursement per case by approximately 600,000. About 2.6 million data could be used for the calculation after having been proved for plausibility in Institut für das Entgeltsystem im Krankenhaus (InEK). The relatively high number of data which were not plausible is based on inferior quality of the data rather than on a more detailed examination of plausibility by the InEK.
Schlüsselwörter

Coding within DRG System / DRG Ratios
The 2006 version of the G-DRG (German Refined Diagnosis Related Group) system includes 954 DRGs in total (76 additional DRGs compared to the 2005 version). Out of these, 912 are included in the case-based lump sum catalogue, and 40 of the 954 DRGs are included in the catalogue of reimbursement cases which do not belong to the case-based lump sum catalogue. The case-based lump sum catalogue 2006 reveals 17 explicit one-day hospitalization DRGs (19 in the year before). In contrast to the decrease of explicit one-day hospitalization DRGs, 25 further implicit one-day hospitalization DRGs are included in the case-based lump sum catalogue 2006 which now covers a total of 241 implicit one-day hospitalization DRGs. Compared to the previous year, the extent of additional reimbursements increased slightly. Appendix 2 (catalogue of additional reimbursements) displays 40 evaluated additional reimbursements (previous year 35). Appendix 4 (additional reimbursements according to § 6, paragraph 1 Krankenhausentgeltgesetz (KHEntgG)) includes 42 additional reimbursement cases based on individual agreements of different hospitals (previous year 36). 
Coding of Autologous Procedures
Depiction of Autologous Procedures in the G-DRGs
By analyzing the depiction of autologous procedures in the G-DRG system on the basis of the DRG Report Browser for the year 2006, it can be shown that autologous procedures were only partially documented in the calculation hospitals. This might be explained by the fact that the documentation of these procedures does not result in a higher classification within the DRG groups and was therefore neglected. Tables 1  and 2 show the DRGs for the autologous donation of blood and the autotransfusion using a Cell Saver and the percentage of patients for which the autologous procedures were documented. Creating a logical row from the depiction of autologous procedures to the coding of the procedures on the basis of OPS catalogue 2006 to further topics such as quality and economy, additional connections between DRGs and autologous procedures become obvious.
Quality Report
According to § 137ff SGB V, German hospitals are obliged to submit a quality report every 2 years containing the following parts: -basic part (data referring to structure and performance), -performance referring to special fields, -quality assurance (BQS (Bundesgeschäftsstelle Qualitäts-sicherung gGmbH) procedures, minimum amount), quality policy, quality management. Quality reports are published via internet, thus being available for all patients and doctors in private practice. This may support/facilitate the choice of the appropriate hospital on the basis of the presented results. In the part with individual texts (quality policy and quality management), the autologous procedures (saving foreign blood) can be presented in detail, and these parts may also be used as marketing instruments. Table 3 displays an overview over the development of minimum regulations in the years [2005] [2006] . There is a striking increase in performance figures in the year 2006 for the case 'knee TEP' (TEP = total endoprosthesis) accompanying the introduction of a minimum amount for this case. According to the report of Gerdelmann (VDAK) during the DRG forum 2005 in Berlin, approximately 950 hospitals provided 'knee TEP' in the year 2004 -but 52% of these hospitals less than 50 times and 25% less than 25 times. In 2006, more than 500 of these hospitals cannot provide the knee TEP operation anymore due to the minimum regulations -apart from a few exceptions referring to temporary regulations. Predominantly, this is due to regulations regarding the appropriate operating unit, but clinical departments such as anesthesiology, pain therapy and post anesthesia care unit (PACU) are also involved. Changing capabilities within operative procedures on the basis of minimum regulations also include the associated autologous procedures. If the number of operations decreases, also the referring performance of autologous procedures, e.g. the use of Cell Saver or autologous donation of blood, are impaired. In this case, cost calculations and economic evaluations have to be adjusted accordingly. 
Minimum Regulation
Procedure Costs
The cost matrix in the DRG Report Browser 2006 presents an overview over the total costs of each DRG with subgroups according to the aggregated cost centers and type of costs. These data constitute a significant benchmarking data pool for evaluation of procedure costs on the basis of the DRGs. A detailed analysis of costs and procedures allows a comparative evaluation of various medical therapeutic procedures. It is the task of hospital controlling to identify inefficient treatment lines and to show possible solutions to optimize procedures. Based on these data, each specialized unit/institute has to re-structure treatment procedures and increase cost efficiency. From the perspective of treatment quality, the head of each specialized unit has the responsibility to advance the internal development of treatment lines which support a decrease in length of hospital stay without a loss of quality. Generally, the economic as well as the medical responsibility will continue to shift towards the specialized units. Apart from medical expertise, this change will require an increasing economic knowledge of the heads of the different departments. These facts are also relevant for the 'blood' topic which is discussed quite controversially in the current literature. Where is the application of foreign blood including all referring costs (collection, distribution, infection rate, allergic reactions, etc.) still indicated? When is the use of autologous procedures such as autologous donation of blood or autotransfusion using a Cell Saver profitable? Previous studies reveal that the donation of foreign blood can imply a higher risk for inpatients with hip or knee TEP to suffer from complications during hospital stay [1] . As this results in an increased length of hospital stay and increased procedure costs, it is obvious that such a situation is extremely disadvantageous in the age of the DRG system. From this point of view it is clear that in planned operations the use of foreign blood without previous attempts to use autologous procedures is obsolete. The findings concerning the comparative evaluation of autologous procedures are much more heterogeneous. Glenngard et al. [2] showed in a comparative cost study -in consideration of opportunity costs such as infection rates, etc. -clear differences in costs. However, these cost studies may not be reproducible in a single case in another hospital, as cost structures differ/vary considerably in different countries, and production costs -especially for donation of autologous blood -depend strongly on organization structure, capacity and rejection. Calculation algorithms which are generally valid and include/consider all opportunity costs should necessarily be established to precisely evaluate the use of autologous procedures on the basis of a DRG cost matrix. 
